About
Evozyne, founded in 2020 in Chicago, provides a generative AI platform for drug discovery and drug development.
Technology & BusinessWhat · How · Which stage
Research Areas生命科学医药MediumEvidence
为药物发现和药物开发提供的生成式AI平台
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2023-09New funding round$81M
Investors · NVentures, Valor Equity Partners, Fidelity, Paragon Biosciences, OrbiMed AdvisorsSource · SVTR Weekly #021
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Evozyne
Generative AI platform for drug discovery and development
Undisclosed · $81M · 2023-09
$81M
United States
BusinessLatest roundTotal raisedDate- Aureka Biotechnologies
AuraIDE™, a platform for generative antibody drug discovery and functional antibody design
Series B · $200M · 2026-08
$200M - Network Bio
Links leading US academic biobanks into a unified research network producing training-ready multimodal datasets, and trains disease-specific AI foundation models on them that transfer across diseases, for disease detection, biomarker discovery and drug development
Undisclosed · $50M · 2026-08
$50M - Ten63 Therapeutics
Applies generative AI models to drug discovery and development
$54M · 2026-03
$54M
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M
Europe
BusinessLatest roundTotal raisedDate- Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M - Healx
AI to discover and develop treatments for rare diseases
Undisclosed · $47M · 2024-08
$47M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Miles Wang 新公司
Develops AI models for drug discovery
— - 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Chicago Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.